This study evaluates the treatment of the symptoms of deep endometriosis with a cannabinoid derivate.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
Hospital Clínic de Barcelona
Barcelona, Catalonia, Spain
Pressure threshold in hypogastrium that induces pain
Pain threshold versus mechanical stimulation in hypogastrium (anterior central L2 dermatoma) measured in kPa
Time frame: day 30 after treatment initiation
Pressure threshold in dermatomes that induces pain
Umbral of pain versus mechanical stimulation in dermatomes L2 anterior, L2 posterior, and T1 of the dominant upper extremity.
Time frame: baseline, day 15, day 30 and day 45
Temperature threshold in dermatomes that induces pain
Umbral sensation versus thermal stimulus (cold heat) in anterior central L2 dermatomes, posterior central L2, and T1 of the dominant upper extremity. Measured in ºC.
Time frame: baseline, day 15, day 30 and day 45
Intensity of the general pain
Intensity of the general pain associated with endometriosis measured by a visual analogue scale (0-10)
Time frame: baseline, day 15, day 30 and day 45
Anxiety and depression combined scale
Anxiety and depression measured with the Scale of Anxiety and Hospital Depression Scale (HADS).
Time frame: baseline, day 15, day 30 and day 45
Quality of Life
Quality of Life measured through the EQ-5D-5L questionnaire.
Time frame: baseline, day 15, day 30 and day 45
Central sensitivity
Central sensitivity measured with the Central Sensitization Inventory (CSI) questionnaire.
Time frame: baseline, day 15, day 30 and day 45
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cognitive disorder measured by a list of words
Cognitive disorder measured by a list of words (immediate memory and retention) and digits (attentional capacity) of the Wechsler Memory Scale (WMS-III).
Time frame: baseline, day 15, day 30 and day 45
about sleep quality
Visual analogue scale 0-10 about sleep quality
Time frame: baseline, day 15, day 30 and day 45